Skip to main content
FluentFlash

DLBCL Non-Hodgkin: Study Guide & Key Concepts

·

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, representing 30-40% of all NHL cases. This aggressive B-cell malignancy challenges pathology and medical students due to its complex diagnostic criteria and clinical significance.

DLBCL arises from germinal center or post-germinal center B cells. It features rapid proliferation of large abnormal lymphoid cells that invade lymph nodes, bone marrow, and extranodal sites.

Mastering DLBCL requires understanding its morphology, immunophenotype, molecular characteristics, and prognostic factors. This knowledge directly impacts diagnostic accuracy and treatment decisions. Use this guide with flashcard study methods to cement these essential concepts for board exams.

DLBCL non-Hodgkin - study with AI flashcards and spaced repetition

Morphology and Diagnostic Criteria of DLBCL

Key Morphologic Features

DLBCL is defined by a proliferation of large lymphoid cells with abundant cytoplasm and prominent nucleoli. These cells are arranged in a diffuse infiltrative pattern without nodular organization. Neoplastic cells measure 20 micrometers or larger, significantly larger than normal lymphocytes.

The histologic background typically contains scattered small lymphocytes, histiocytes, and eosinophils mixed among the large B cells. This polymorphic background is normal and does not exclude DLBCL diagnosis.

Diagnostic Workup Process

DLBCL diagnosis requires the World Health Organization (WHO) classification. This combines morphologic assessment with immunophenotypic and molecular findings rather than relying on morphology alone.

Diagnosis requires careful examination of tissue biopsies, usually lymph node or extranodal tissue, using light microscopy. Immunohistochemistry studies confirm B-cell origin and assess prognostically important markers:

  • CD20 (B-cell marker)
  • CD10 (germinal center marker)
  • BCL6 (germinal center marker)
  • MUM1 (post-germinal center marker)
  • Ki-67 (proliferation marker)

High Proliferation Rate

The tumor cells show a high proliferation rate, often exceeding 80% as measured by Ki-67 immunostaining. This rapid growth distinguishes DLBCL from indolent lymphomas and reactive processes.

Understanding morphologic features is crucial for recognizing DLBCL on histopathology. You must distinguish it from other lymphomas and reactive processes that may mimic malignancy.

Immunophenotype and Cell of Origin Classification

B-Cell Immunophenotype Pattern

DLBCL follows a B-cell phenotype pattern. Neoplastic cells typically express:

  • CD20 (B-cell marker)
  • CD45 (pan-leukocyte marker)
  • Monoclonal surface immunoglobulin (either kappa or lambda)

This monoclonal immunoglobulin expression distinguishes neoplastic B cells from the polyclonal pattern seen in reactive processes.

Cell of Origin Classification System

A critical classification divides DLBCL into two subtypes based on cell of origin (COO). The Hans algorithm uses immunostains for CD10, BCL6, and MUM1 to classify cases:

  1. Germinal Center B-cell (GCB) type: Better prognosis, superior five-year survival rates
  2. Activated B-cell (ABC) type: More aggressive behavior, poorer survival outcomes

GCB-type DLBCL generally has prognosis approximately 10-15% higher than ABC-type cases. This difference relates to inherent biologic differences and treatment responsiveness.

Double-Hit and Triple-Hit Assessment

DLBCL cases are assessed for BCL2 and MYC protein coexpression. Double-hit lymphomas show concurrent MYC and BCL2 translocations. Triple-hit lymphomas additionally include BCL6 translocations.

These aggressive subtypes carry significantly worse prognosis and poor responses to standard therapies. Identification through FISH testing is essential for treatment planning.

Molecular and Genetic Features

Recurrent Chromosomal Translocations

DLBCL arises from acquired genetic abnormalities in B cells. The most common recurrent translocations include:

  • t(14;18) involving IGH and BCL2 genes (20-25% of cases)
  • t(8;14) involving MYC gene (10-15% of cases)
  • Complex karyotypes

The t(14;18) translocation often indicates transformation from low-grade follicular lymphoma. MYC translocations confer particularly poor prognosis, especially when concurrent with BCL2 or BCL6 translocations.

Important Gene Mutations

Beyond chromosomal translocations, DLBCL shows frequent mutations in key genes:

  • TP53 (present in 25-30% of cases, carries major prognostic implications)
  • CREBBP (epigenetic modifier)
  • EP300 (histone-modifying enzyme)
  • KMT2D (histone-modifying enzyme)
  • MYD88 (B-cell signaling pathway)
  • CD79B (B-cell signaling pathway)

Prognostic Scoring Systems

The International Prognostic Index (IPI) combines clinical factors to predict treatment outcomes:

  • Age (over 60 years carries worse prognosis)
  • Stage (III-IV more advanced)
  • LDH level (elevated indicates higher burden)
  • Performance status (functional capacity)
  • Number of extranodal sites (more sites indicate worse prognosis)

Gene expression profiling identifies distinct molecular subtypes with different survival outcomes and therapeutic sensitivities. Molecular testing increasingly complements histopathologic diagnosis and guides personalized treatment approaches.

Clinical Presentation and Staging

Typical Presenting Symptoms

Patients with DLBCL typically present with rapid onset of lymphadenopathy. Constitutional symptoms commonly occur:

  • Fever
  • Night sweats
  • Unintentional weight loss

The rapid growth rate means patients often present with advanced stage III-IV disease at diagnosis.

Common Sites of Involvement

The most common sites of lymph node involvement are mediastinal, abdominal, and pelvic regions. However, any nodal or extranodal site can be affected.

Extranodal disease is present at diagnosis in approximately 40% of patients. Common organs involved include:

  • Gastrointestinal tract
  • Bone marrow
  • Liver
  • Central nervous system
  • Bone

Laboratory Findings and Staging Workup

Laboratory findings typically reveal elevated serum LDH, which serves as both a prognostic marker and indicator of tumor burden. Complete staging evaluation includes:

  • PET-CT imaging to assess disease extent
  • Bone marrow biopsy to evaluate marrow involvement
  • CNS prophylaxis consideration in high-risk patients
  • Tissue biopsy with histopathology and immunophenotyping

Prognosis Based on Risk Stratification

The International Prognostic Index helps determine treatment intensity and prognosis. Five-year survival rates vary significantly:

  • Low-risk patients: approximately 90% survival
  • High-risk patients: less than 40% survival

Understanding clinical presentation patterns helps students recognize suggestive findings that warrant diagnostic investigation.

Treatment Approaches and Prognostic Factors

Standard First-Line Treatment

The standard first-line treatment is R-CHOP, which combines:

  • Rituximab (anti-CD20 monoclonal antibody)
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone

R-CHOP has substantially improved outcomes compared to CHOP chemotherapy alone. Treatment intensity and duration depend on prognostic factors based on disease stage and IPI score.

Response Assessment and Outcomes

Response to initial therapy is assessed using PET-CT imaging. Key outcomes include:

  • Complete response indicates excellent prognosis
  • Partial response may warrant consolidative autologous stem cell transplantation
  • Patients achieving complete remission have significantly better long-term outcomes

Treatment Considerations by Subtype

The cell of origin subtype influences treatment response. GCB-type cases show better outcomes to standard R-CHOP compared to ABC-type cases. Some ABC-type cases may benefit from addition of bortezomib (proteasome inhibitor) to standard therapy.

Secondary CNS prophylaxis is considered for high-risk patients to prevent leptomeningeal involvement. Novel therapeutic approaches for relapsed or refractory disease include CAR-T cell therapy and targeted agents.

Key Prognostic Factors Summary

Multiple factors predict treatment outcomes:

  • International Prognostic Index score
  • Cell of origin subtype (GCB vs ABC)
  • Double-hit or triple-hit status
  • TP53 mutation presence
  • Early response to therapy

Understanding treatment paradigms and prognostic factors helps students appreciate how pathologic and molecular findings directly impact clinical management and patient outcomes.

Start Studying Diffuse Large B-Cell Lymphoma

Master DLBCL pathology with evidence-based flashcard learning. Create customized study decks covering morphology, immunophenotype, genetics, clinical features, and prognostic factors to ace your pathology exams.

Create Free Flashcards

Frequently Asked Questions

What is the most important diagnostic distinction between DLBCL and Burkitt lymphoma?

Both are aggressive B-cell lymphomas with high proliferation rates, but they differ in key ways. Burkitt lymphoma is defined by the pathognomonic t(8;14) translocation involving MYC. It shows a starry-sky histologic pattern with numerous tingible body macrophages.

DLBCL lacks the MYC translocation requirement and shows larger, more polymorphic cells with increased cytoplasm. However, some DLBCL cases do contain MYC translocations, classified as double-hit or triple-hit lymphomas.

The critical distinction is that Burkitt lymphoma is defined by morphology plus MYC translocation. DLBCL is more of a diagnosis of exclusion. Additionally, Burkitt lymphoma typically presents in younger patients with very rapid growth, while DLBCL has a broader age range and slightly slower growth rate.

Immunophenotypically, both express CD20, but detailed morphologic assessment and cytogenetic testing are essential for accurate classification.

How does the cell of origin classification impact DLBCL prognosis and treatment?

The cell of origin (COO) classification divides DLBCL into two subtypes with major prognostic implications.

Germinal center B-cell (GCB) type generally has superior outcomes with five-year survival rates approximately 10-15% higher than ABC-type cases.

Activated B-cell (ABC) type shows more aggressive biologic behavior. ABC-type cases show more frequent mutations in genes like MYD88 and CD79B that promote B-cell receptor signaling.

From a treatment perspective, ABC-type cases may benefit from addition of bortezomib (proteasome inhibitor) to standard R-CHOP therapy in some protocols. The Hans algorithm uses immunostains for CD10, BCL6, and MUM1 to determine COO in routine practice.

Some patients have intermediate or unclassifiable features, which may require gene expression profiling for definitive classification. Understanding COO helps pathology students appreciate how immunophenotypic findings directly translate into prognostic information that guides clinical decision-making and treatment intensity selection.

What are double-hit and triple-hit lymphomas, and why do they matter?

Double-hit lymphomas are DLBCL cases with concurrent translocations involving both MYC and BCL2 genes. Triple-hit lymphomas additionally include a BCL6 translocation. These genetic hits are identified through fluorescence in situ hybridization (FISH) testing.

These represent particularly aggressive subtypes with significantly worse prognosis compared to standard DLBCL. Patients with double-hit lymphomas have substantially lower survival rates and show poor responses to standard R-CHOP therapy.

The poor prognosis relates to the combined oncogenic effects of these genes. MYC drives proliferation while BCL2 prevents apoptosis, creating cells resistant to standard therapies. Often intensified treatment approaches are required, including stem cell transplantation.

These cases may be recognized on routine histology if they show overlapping features with high proliferation and frequent apoptotic figures. However, FISH testing is required for definitive identification.

For medical students, recognizing the clinical significance of these genetic combinations is critical. It explains why some DLBCL patients require aggressive treatment despite having morphologically similar tumors to standard DLBCL cases.

How is DLBCL distinguished from reactive lymphadenopathy or inflammation?

Distinguishing DLBCL from reactive processes is a fundamental diagnostic challenge in pathology. Key morphologic features supporting DLBCL diagnosis include:

  • Presence of large cells with high mitotic rate
  • Diffuse pattern without nodular architecture
  • Monomorphic cellular composition
  • Effacement of normal lymph node structure

Reactive lymphadenopathy preserves lymph node architecture with identifiable germinal centers. It maintains a polymorphic cellular infiltrate with numerous small lymphocytes and macrophages.

Immunophenotyping is essential for diagnosis. DLBCL shows monoclonal surface immunoglobulin expression (either kappa or lambda light chain restriction) and CD20 expression. Reactive processes show polyclonal immunoglobulin expression with mixed light chain restriction.

Flow cytometry can identify an abnormal B-cell population with light chain restriction and increased CD10 or other markers. Clonality studies using immunoglobulin gene rearrangement testing demonstrate monoclonal patterns in DLBCL compared to polyclonal patterns in reactive conditions.

Some cases remain diagnostically challenging. These require correlation with clinical presentation, imaging findings, and sometimes repeated biopsy for definitive diagnosis.

Why are flashcards particularly effective for learning DLBCL concepts?

Flashcards leverage spaced repetition and active recall, which are scientifically proven learning techniques especially valuable for complex pathology topics. DLBCL involves multiple interconnected concepts that benefit from systematic review.

DLBCL requires understanding morphology, immunophenotype, genetics, clinical features, and prognostic factors. Creating flashcards forces you to distill key information into concise, testable formats. This improves retention and identifies knowledge gaps.

Active recall through flashcard self-testing produces stronger memory encoding than passive reading. Flashcards allow focused study of high-yield facts like morphologic criteria, key immunostains (CD20, CD10, BCL6, MUM1), prognostic markers (IPI score, double-hit status), and treatment paradigms.

Spaced repetition systems optimize review timing to reinforce information before forgetting occurs. This is critical for mastering DLBCL's complex diagnostic criteria and prognostic algorithms. Digital flashcard platforms enable efficient organization by topic, allowing you to focus on weaker areas while rapidly reviewing mastered material.

For board exam preparation, flashcards simulate the rapid information retrieval and application required during high-stakes examinations.